{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:09:20Z","timestamp":1790143760662,"version":"4.0.1"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The French, American, and British (FAB) classification system for acute myeloid leukemia (AML) is extensively used and is incorporated into the AML, not otherwise specified (NOS) category in the 2016 WHO edition of myeloid neoplasm classification. While recent data proposes that FAB classification does not provide additional prognostic information for patients for whom <jats:italic>NPM1<\/jats:italic> status is available, it is unknown whether FAB still retains a current prognostic role in predicting outcome of AML patients undergoing allogeneic stem cell transplantation. Using the European Society of Blood and Bone Marrow Transplantation registry we analyzed outcome of 1690 patients transplanted in CR1 to determine if FAB classification provides additional prognostic value. Multivariate analysis revealed that M6\/M7 patients had decreased leukemia free survival (hazard ratio (HR) of 1.41, 95% confidence interval (CI), 1.01\u20131.99; <jats:italic>P =<\/jats:italic> .046) in addition to increased nonrelapse mortality (NRM) rates (HR, 1.79; 95% CI, 1.06\u20133.01; <jats:italic>P =<\/jats:italic> .028) compared with other FAB types. In the <jats:italic>NPM1<jats:sup>wt<\/jats:sup><\/jats:italic> AML, NOS cohort, FAB M6\/M7 was also associated with increased NRM (HR, 2.17; 95% CI, 1.14\u20134.16; <jats:italic>P =<\/jats:italic> .019). Finally, in <jats:italic>FLT3\u2010ITD<jats:sup>+<\/jats:sup><\/jats:italic> patients, multivariate analyses revealed that specific FAB types were tightly associated with adverse outcome. In conclusion, FAB classification may predict outcome following transplantation in AML, NOS patients.<\/jats:p>","DOI":"10.1002\/ajh.24640","type":"journal-article","created":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T23:16:43Z","timestamp":1483571803000},"page":"344-350","source":"Crossref","is-referenced-by-count":33,"title":["Impact of <scp>FAB<\/scp> classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in <scp>CR<\/scp>1: An analysis of 1690 patients from the acute leukemia working party of <scp>EBMT<\/scp>"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5294-3524","authenticated-orcid":false,"given":"Jonathan","family":"Canaani","sequence":"first","affiliation":[{"name":"Hematology Division, Chaim Sheba Medical Center, Tel Hashomer Tel Aviv University  Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Beohou","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Clinique et Th\u00e9rapie Cellulaire, H\u00f4pital Saint\u2010Antoine, Universite Pierre &amp; Marie Curie Paris France"},{"name":"EBMT Acute Leukemia Working Party office, H\u00f4pital Saint\u2010Antoine Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Clinique et Th\u00e9rapie Cellulaire, H\u00f4pital Saint\u2010Antoine, Universite Pierre &amp; Marie Curie Paris France"},{"name":"EBMT Acute Leukemia Working Party office, H\u00f4pital Saint\u2010Antoine Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Soci\u00e9","sequence":"additional","affiliation":[{"name":"EBMT Acute Leukemia Working Party office, H\u00f4pital Saint\u2010Antoine Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer Toulouse, Oncopole Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa","family":"Volin","sequence":"additional","affiliation":[{"name":"HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cornelissen","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus MC Cancer Institute, University Medical Center Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Milpied","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, H\u00f4pital Haut\u2010leveque Pessac France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde\u2010Dahl","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinic for Cancer, Surgery and Transplantation Oslo University Hospital, Rikshospitalet Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deconinck","sequence":"additional","affiliation":[{"name":"Service d`H\u00e9matologie Hopital Jean Minjoz Besancon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Fegueux","sequence":"additional","affiliation":[{"name":"D\u00e9partement d`H\u00e9matologie Clinique CHU Lapeyronie Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[{"name":"Centre de Recherche en Canc\u00e9rologie de Marseille Programme de Transplantation &amp; Therapie Cellulaire Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Clinique et Th\u00e9rapie Cellulaire, H\u00f4pital Saint\u2010Antoine, Universite Pierre &amp; Marie Curie Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[{"name":"Hematology Division, Chaim Sheba Medical Center, Tel Hashomer Tel Aviv University  Israel"},{"name":"EBMT Acute Leukemia Working Party office, H\u00f4pital Saint\u2010Antoine Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-364265"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1323"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-431122"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047225"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4938"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9868"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651562"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.170"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.4973"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8500"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.070235"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401832"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.5940"},{"key":"e_1_2_5_16_1","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood.V65.5.1191.1191","article-title":"Bone marrow transplantation for acute nonlymphocytic leukemia in first remission: analysis of prognostic factors","volume":"65","author":"Bostrom B","year":"1985","journal-title":"Blood"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb02188.x"},{"key":"e_1_2_5_18_1","first-page":"247","article-title":"Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis","volume":"13","author":"Fagioli F","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462440"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050162"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011133115435"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb04444.x"},{"key":"e_1_2_5_26_1","first-page":"993","article-title":"Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC\u2010GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups","volume":"17","author":"Keating S","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.060"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.220"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32835ec91f"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578070"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.181"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1099-0"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:26:14Z","timestamp":1695561974000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1002\/ajh.24640"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24640","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,7]]}}}